Adjuvant treatment for breast cancer

Surgery (United Kingdom)

Volumn 31, Issue 1, 2013, Pages 37-40

  Passant, Helen ^a   Borley, Annabel ^a  

^a VELINDRE CANCER CENTRE   (United Kingdom)

Author keywords

Aromatase inhibitors; chemotherapy; hormonal therapy; radiotherapy; tamoxifen; trastuzumab

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; EPIRUBICIN; EXEMESTANE; FLUOROURACIL; LETROZOLE; METHOTREXATE; PERTUZUMAB; TRASTUZUMAB;

AGE DISTRIBUTION; ARTICLE; BREAST CANCER; BREAST TUMOR; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CARDIOMYOPATHY; DISTANT METASTASIS; DRUG EFFICACY; DRUG SAFETY; HEART DISEASE; HUMAN; MALE BREAST CANCER; MUSCULOSKELETAL DISEASE; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; RECURRENT CANCER; RISK ASSESSMENT;

EID: 84872039027     PISSN: 02639319     EISSN: 18781764     Source Type: Journal    
DOI: 10.1016/j.mpsur.2012.10.015     Document Type: Review

References (16)

1. Cancer Research UK statistics http://info.cancerresearchuk.org/ cancerstats/types/breast/survival.
2. NICE Clinical guideline 80. National Collaborating Centre for Cancer. www.nice.org.uk/CG80.
3. Early Breast Cancer Trialists Collaborative Group (EBCTCG) Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15 year survival: an overview of the randomised trials Lancet 366 2005 2087 2106
4. The Start Trialists Group The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial Lancet 371 2008 1098 1107
5. S. Hetelekidis, S.J. Schnitt, and B. Silver The significance of extracapsular extension of axillary lymph node metastases in early breast cancer Int J Radiat Oncol Biol Phys 46 2000 31 34
6. N. Antonini, H. Jones, and J.C. Horiot Effect of age and radiation dose on local control after breast conserving treatment: EORTC trial 22881-10882 Radiother Oncol 82 2007 265 271
7. T. Sorlie, C.M. Perou, and R. Tibshirani Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci USA 98 2001 Sep 11 10869 10874
8. G. Bonadonna, E. Brusamolino, and P. Valagussa Combination chemotherapy as an adjuvant treatment in operable breast cancer N Engl J Med 294 1976 405 410
9. EBCTCG Effects of chemotherapy and hormone therapy for early breast cancer on recurrence and 15 year survival: an overview of the randomised trials Lancet 365 2005 1687 1717
10. R.C. Coombes, E. Hall, and L.J. Gibson A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer N Engl J Med 350 2004 1081 1092
11. R. Jakesz, W. Jonat, and M. Gnant Switching of postmenopausal women with hormonal responsive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial Lancet 366 2005 455 462
12. P.E. Goss, J. Inge, and S. Martino Randomized trial of letrazole following tamoxifen as extended adjuvant therapy in receptor positive breast cancer: updated findings from NCIC CTG MA.17 J Natl Cancer Inst 97 2005 1262 1271
13. A. Howell, J. Cuzick, and M. Baum on behalf of the ATAC Triallists group. Results of the ATAC(Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for Breast Cancer Lancet 365 2005 60 62
14. D.M. Reid, J. Doughty, and R. Eastell Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group Cancer Treat Rev 34 2008 S1 S18
15. Piccart-Gebhart, Procter, and Leyland-Jones Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 2005 1659 1672
16. A.L. Jones, M. Barlow, and P.J. Barrett-Lee Management of cardiac health in trastuzumab treated patients with breast cancer: updated United Kingdom National Cancer Research Institute Recommendations for monitoring Br J Cancer 100 2009 684 692